SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Similar to the mechanism of action of sodium-glucose cotransporter 2 inhibitors, GLP-1RAs improve NAFLD by suppressing hepatic inflammation and oxidative stress, enhancing lipid metabolism, and promoting autophagy [62].